<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>9259934</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">35812093</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">9259934</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.3389/fneur.2022.902912</article-id></all-ids><extracted-table><table-id>T1</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical characteristics of the group with TAO and HCs.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="T1"><label>Table 1</label><caption><p>Demographic and clinical characteristics of the group with TAO and HCs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Items</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>TAO group (<italic>n</italic> = 30)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>HCs (<italic>n</italic> = 30)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold><italic>p</italic>-value</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">43.27 ± 14.20</td><td valign="top" align="center" rowspan="1" colspan="1">43.47 ± 13.62</td><td valign="top" align="center" rowspan="1" colspan="1">0.956</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gender (female/male)</td><td valign="top" align="center" rowspan="1" colspan="1">18/12</td><td valign="top" align="center" rowspan="1" colspan="1">18/12</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.999</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Disease duration (months)</td><td valign="top" align="center" rowspan="1" colspan="1">10.03 ± 11.53</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CAS</td><td valign="top" align="center" rowspan="1" colspan="1">3.17 ± 1.05</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FT3 (pmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">4.67 ± 0.76</td><td valign="top" align="center" rowspan="1" colspan="1">4.92 ± 0.96</td><td valign="top" align="center" rowspan="1" colspan="1">0.337</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FT4 (pmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">16.39 ± 2.83</td><td valign="top" align="center" rowspan="1" colspan="1">16.80 ± 2.09</td><td valign="top" align="center" rowspan="1" colspan="1">0.529</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TSH (mIU/L)</td><td valign="top" align="center" rowspan="1" colspan="1">1.77 ± 1.83</td><td valign="top" align="center" rowspan="1" colspan="1">1.63 ± 1.13</td><td valign="top" align="center" rowspan="1" colspan="1">0.679</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Visual acuity</td><td valign="top" align="center" rowspan="1" colspan="1">0.76 ± 0.15</td><td valign="top" align="center" rowspan="1" colspan="1">0.97 ± 0.15</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Exophthalmos (mm)</td><td valign="top" align="center" rowspan="1" colspan="1">20.20 ± 3.57</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><bold>QoL scores</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Visual functioning</td><td valign="top" align="center" rowspan="1" colspan="1">56.98 ± 31.36</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Appearance</td><td valign="top" align="center" rowspan="1" colspan="1">65.60 ± 21.27</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total score of HARS</td><td valign="top" align="center" rowspan="1" colspan="1">17.13 ± 7.95</td><td valign="top" align="center" rowspan="1" colspan="1">2.50 ± 1.20</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total score of HDRS</td><td valign="top" align="center" rowspan="1" colspan="1">16.53 ± 6.95</td><td valign="top" align="center" rowspan="1" colspan="1">2.33 ± 1.67</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total score of MoCA</td><td valign="top" align="center" rowspan="1" colspan="1">25.87 ± 3.35</td><td valign="top" align="center" rowspan="1" colspan="1">28.77 ± 1.10</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><p><italic>Data were presented as mean ± SD</italic>.</p><p><italic>CAS, clinical activity score; FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid-stimulating hormone; QoL, quality of life; HDRS, Hamilton Depression Rating Scale; HARS, Hamilton Anxiety Rating Scale; MoCA, Montreal Cognitive Assessment; TAO, thyroid-associated ophthalmopathy; HCs, healthy controls</italic>.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical characteristics of the group with TAO and HCs.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left">Items</th><th valign="top" align="center">TAO group (n = 30)</th><th valign="top" align="center">HCs (n = 30)</th><th valign="top" align="center">p-value</th></tr></thead><tbody><tr><td valign="top" align="left">Age (years)</td><td valign="top" align="center">43.27 ± 14.20</td><td valign="top" align="center">43.47 ± 13.62</td><td valign="top" align="center">0.956</td></tr><tr><td valign="top" align="left">Gender (female/male)</td><td valign="top" align="center">18/12</td><td valign="top" align="center">18/12</td><td valign="top" align="center">&gt;0.999</td></tr><tr><td valign="top" align="left">Disease duration (months)</td><td valign="top" align="center">10.03 ± 11.53</td><td valign="top" align="center">-</td><td/></tr><tr><td valign="top" align="left">CAS</td><td valign="top" align="center">3.17 ± 1.05</td><td valign="top" align="center">-</td><td/></tr><tr><td valign="top" align="left">FT3 (pmol/L)</td><td valign="top" align="center">4.67 ± 0.76</td><td valign="top" align="center">4.92 ± 0.96</td><td valign="top" align="center">0.337</td></tr><tr><td valign="top" align="left">FT4 (pmol/L)</td><td valign="top" align="center">16.39 ± 2.83</td><td valign="top" align="center">16.80 ± 2.09</td><td valign="top" align="center">0.529</td></tr><tr><td valign="top" align="left">TSH (mIU/L)</td><td valign="top" align="center">1.77 ± 1.83</td><td valign="top" align="center">1.63 ± 1.13</td><td valign="top" align="center">0.679</td></tr><tr><td valign="top" align="left">Visual acuity</td><td valign="top" align="center">0.76 ± 0.15</td><td valign="top" align="center">0.97 ± 0.15</td><td valign="top" align="center">&lt;0.001</td></tr><tr><td valign="top" align="left">Exophthalmos (mm)</td><td valign="top" align="center">20.20 ± 3.57</td><td valign="top" align="center">-</td><td/></tr><tr><td valign="top" align="left" colspan="4">QoL scores</td></tr><tr><td valign="top" align="left">Visual functioning</td><td valign="top" align="center">56.98 ± 31.36</td><td valign="top" align="center">-</td><td/></tr><tr><td valign="top" align="left">Appearance</td><td valign="top" align="center">65.60 ± 21.27</td><td valign="top" align="center">-</td><td/></tr><tr><td valign="top" align="left">Total score of HARS</td><td valign="top" align="center">17.13 ± 7.95</td><td valign="top" align="center">2.50 ± 1.20</td><td valign="top" align="center">&lt;0.001</td></tr><tr><td valign="top" align="left">Total score of HDRS</td><td valign="top" align="center">16.53 ± 6.95</td><td valign="top" align="center">2.33 ± 1.67</td><td valign="top" align="center">&lt;0.001</td></tr><tr><td valign="top" align="left">Total score of MoCA</td><td valign="top" align="center">25.87 ± 3.35</td><td valign="top" align="center">28.77 ± 1.10</td><td valign="top" align="center">&lt;0.001</td></tr></tbody></table></div>Data were presented as mean ± SD.CAS, clinical activity score; FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid-stimulating hormone; QoL, quality of life; HDRS, Hamilton Depression Rating Scale; HARS, Hamilton Anxiety Rating Scale; MoCA, Montreal Cognitive Assessment; TAO, thyroid-associated ophthalmopathy; HCs, healthy controls.</transformed-table></extracted-table><extracted-table><table-id>T2</table-id><table-label>Table 2</table-label><table-caption>Brain areas with significantly different short- and long-range FCD values between groups (P &lt; 0.05, cluster-level FWE-corrected).</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="T2"><label>Table 2</label><caption><p>Brain areas with significantly different short- and long-range FCD values between groups (<italic>P</italic> &lt; 0.05, cluster-level FWE-corrected).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="3" rowspan="1"><bold>MNI coordinates</bold></th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Brain regions/conditions</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>BA</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>X</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Y</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Z</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Cluster size (number of voxels)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold><italic>t</italic>-value</bold></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="7" rowspan="1"><bold>Short-range FCD:</bold></td></tr><tr><td valign="top" align="left" colspan="7" rowspan="1"><bold>TAO group</bold><bold>&gt;</bold><bold>HCs</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SFGdor.L/R,</td><td valign="top" align="center" rowspan="1" colspan="1">9/10/11/46/47</td><td valign="top" align="center" rowspan="1" colspan="1">−24</td><td valign="top" align="center" rowspan="1" colspan="1">57</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1,140</td><td valign="top" align="center" rowspan="1" colspan="1">5.746</td></tr><tr><td valign="top" align="left" colspan="7" rowspan="1">MFG.L,</td></tr><tr><td valign="top" align="left" colspan="7" rowspan="1">SFGmed.L/R,</td></tr><tr><td valign="top" align="left" colspan="7" rowspan="1">ORBmid.L,</td></tr><tr><td valign="top" align="left" colspan="7" rowspan="1">ORBinf.L,</td></tr><tr><td valign="top" align="left" colspan="7" rowspan="1">ORBsup.L</td></tr><tr><td valign="top" align="left" colspan="7" rowspan="1"><bold>TAO group</bold><bold>&lt;</bold><bold>HCs</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PoCG.L, SPG.L, IPL.L</td><td valign="top" align="center" rowspan="1" colspan="1">2/3</td><td valign="top" align="center" rowspan="1" colspan="1">−45</td><td valign="top" align="center" rowspan="1" colspan="1">−27</td><td valign="top" align="center" rowspan="1" colspan="1">48</td><td valign="top" align="center" rowspan="1" colspan="1">482</td><td valign="top" align="center" rowspan="1" colspan="1">−6.057</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PoCG.R</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">39</td><td valign="top" align="center" rowspan="1" colspan="1">−33</td><td valign="top" align="center" rowspan="1" colspan="1">57</td><td valign="top" align="center" rowspan="1" colspan="1">130</td><td valign="top" align="center" rowspan="1" colspan="1">−4.400</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SMA.R, PCL.L</td><td valign="top" align="center" rowspan="1" colspan="1">4/6</td><td valign="top" align="center" rowspan="1" colspan="1">−3</td><td valign="top" align="center" rowspan="1" colspan="1">−21</td><td valign="top" align="center" rowspan="1" colspan="1">60</td><td valign="top" align="center" rowspan="1" colspan="1">109</td><td valign="top" align="center" rowspan="1" colspan="1">−4.466</td></tr><tr><td valign="top" align="left" colspan="7" rowspan="1"><bold>Long-range FCD:</bold></td></tr><tr><td valign="top" align="left" colspan="7" rowspan="1"><bold>TAO group</bold><bold>&gt;</bold><bold>HCs</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MFG.L, ORBsup.L, SFGdor.L</td><td valign="top" align="center" rowspan="1" colspan="1">10/11/46/47</td><td valign="top" align="center" rowspan="1" colspan="1">−24</td><td valign="top" align="center" rowspan="1" colspan="1">57</td><td valign="top" align="center" rowspan="1" colspan="1">−3</td><td valign="top" align="center" rowspan="1" colspan="1">114</td><td valign="top" align="center" rowspan="1" colspan="1">4.759</td></tr><tr><td valign="top" align="left" colspan="7" rowspan="1"><bold>TAO group</bold><bold>&lt;</bold><bold>HCs</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PoCG.L, SPG.L, IPL.L</td><td valign="top" align="center" rowspan="1" colspan="1">2/3</td><td valign="top" align="center" rowspan="1" colspan="1">−45</td><td valign="top" align="center" rowspan="1" colspan="1">−27</td><td valign="top" align="center" rowspan="1" colspan="1">48</td><td valign="top" align="center" rowspan="1" colspan="1">482</td><td valign="top" align="center" rowspan="1" colspan="1">−6.057</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PoCG.R</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">39</td><td valign="top" align="center" rowspan="1" colspan="1">−30</td><td valign="top" align="center" rowspan="1" colspan="1">54</td><td valign="top" align="center" rowspan="1" colspan="1">234</td><td valign="top" align="center" rowspan="1" colspan="1">−4.589</td></tr></tbody></table><table-wrap-foot><p><italic>FCD, Functional connectivity density; FWE, family-wise error; BA, Brodmann's areas; MNI, Montreal Neurologic Institute; TAO, thyroid associated ophthalmopathy; HCs, healthy controls; R, right; L, left; SFGdor, dorsolateral part of superior frontal gyrus; MFG, middle frontal gyrus; SFGmed, medial part of superior frontal gyrus; ORBmid, orbital part of middle frontal gyrus; ORBinf, orbital part of Inferior frontal gyrus; ORBsup, orbital part of superior frontal gyrus; PoCG, postcentral gyrus; SPG, superior parietal gyrus; IPL, inferior parietal; SMA, supplementary motor area; PCL, paracentral lobule</italic>.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Brain areas with significantly different short- and long-range FCD values between groups (P &lt; 0.05, cluster-level FWE-corrected).</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th/><th/><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="3">MNI coordinates</th><th/><th/></tr><tr><th valign="top" align="left">Brain regions/conditions</th><th valign="top" align="center">BA</th><th valign="top" align="center">X</th><th valign="top" align="center">Y</th><th valign="top" align="center">Z</th><th valign="top" align="center">Cluster size (number of voxels)</th><th valign="top" align="center">t-value</th></tr></thead><tbody><tr><td valign="top" align="left" colspan="7">Short-range FCD:</td></tr><tr><td valign="top" align="left" colspan="7">TAO group&gt;HCs</td></tr><tr><td valign="top" align="left">SFGdor.L/R,</td><td valign="top" align="center">9/10/11/46/47</td><td valign="top" align="center">−24</td><td valign="top" align="center">57</td><td valign="top" align="center">0</td><td valign="top" align="center">1,140</td><td valign="top" align="center">5.746</td></tr><tr><td valign="top" align="left" colspan="7">MFG.L,</td></tr><tr><td valign="top" align="left" colspan="7">SFGmed.L/R,</td></tr><tr><td valign="top" align="left" colspan="7">ORBmid.L,</td></tr><tr><td valign="top" align="left" colspan="7">ORBinf.L,</td></tr><tr><td valign="top" align="left" colspan="7">ORBsup.L</td></tr><tr><td valign="top" align="left" colspan="7">TAO group&lt;HCs</td></tr><tr><td valign="top" align="left">PoCG.L, SPG.L, IPL.L</td><td valign="top" align="center">2/3</td><td valign="top" align="center">−45</td><td valign="top" align="center">−27</td><td valign="top" align="center">48</td><td valign="top" align="center">482</td><td valign="top" align="center">−6.057</td></tr><tr><td valign="top" align="left">PoCG.R</td><td valign="top" align="center">3</td><td valign="top" align="center">39</td><td valign="top" align="center">−33</td><td valign="top" align="center">57</td><td valign="top" align="center">130</td><td valign="top" align="center">−4.400</td></tr><tr><td valign="top" align="left">SMA.R, PCL.L</td><td valign="top" align="center">4/6</td><td valign="top" align="center">−3</td><td valign="top" align="center">−21</td><td valign="top" align="center">60</td><td valign="top" align="center">109</td><td valign="top" align="center">−4.466</td></tr><tr><td valign="top" align="left" colspan="7">Long-range FCD:</td></tr><tr><td valign="top" align="left" colspan="7">TAO group&gt;HCs</td></tr><tr><td valign="top" align="left">MFG.L, ORBsup.L, SFGdor.L</td><td valign="top" align="center">10/11/46/47</td><td valign="top" align="center">−24</td><td valign="top" align="center">57</td><td valign="top" align="center">−3</td><td valign="top" align="center">114</td><td valign="top" align="center">4.759</td></tr><tr><td valign="top" align="left" colspan="7">TAO group&lt;HCs</td></tr><tr><td valign="top" align="left">PoCG.L, SPG.L, IPL.L</td><td valign="top" align="center">2/3</td><td valign="top" align="center">−45</td><td valign="top" align="center">−27</td><td valign="top" align="center">48</td><td valign="top" align="center">482</td><td valign="top" align="center">−6.057</td></tr><tr><td valign="top" align="left">PoCG.R</td><td valign="top" align="center">3</td><td valign="top" align="center">39</td><td valign="top" align="center">−30</td><td valign="top" align="center">54</td><td valign="top" align="center">234</td><td valign="top" align="center">−4.589</td></tr></tbody></table></div>FCD, Functional connectivity density; FWE, family-wise error; BA, Brodmann's areas; MNI, Montreal Neurologic Institute; TAO, thyroid associated ophthalmopathy; HCs, healthy controls; R, right; L, left; SFGdor, dorsolateral part of superior frontal gyrus; MFG, middle frontal gyrus; SFGmed, medial part of superior frontal gyrus; ORBmid, orbital part of middle frontal gyrus; ORBinf, orbital part of Inferior frontal gyrus; ORBsup, orbital part of superior frontal gyrus; PoCG, postcentral gyrus; SPG, superior parietal gyrus; IPL, inferior parietal; SMA, supplementary motor area; PCL, paracentral lobule.</transformed-table></extracted-table></extracted-tables-set>